[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630170":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":46,"locations":52,"responsibleParty":138,"collaborators":27,"id":140,"slug":141,"hasResults":142,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":27,"eligibilityCriteria":145,"healthyVolunteers":142,"sex":146,"minAge":147,"maxAge":27,"enrollmentInfo":148,"targetDuration":27,"studyType":151,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":55,"whyStopped":27,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"Alcon Research","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Clareon Vivity Pro IOL \u002F Clareon Vivity IOL (Sub-Study B)","OTHER","Clareon Vivity Pro IOL implanted in one eye, with Clareon Vivity IOL in the fellow eye, as randomized",[13,14,15],"Device: Clareon Vivity Pro IOL","Device: Clareon Vivity IOL","Procedure: Cataract Surgery",{"label":17,"type":10,"description":18,"interventionNames":19},"Clareon Vivity Pro IOL \u002F TECNIS PureSee IOL (Sub-Study C)","Clareon Vivity Pro IOL implanted in one eye, with TECNIS PureSee IOL in the fellow eye, as randomized",[13,20,15],"Device: TECNIS PureSee IOL",[22,28,32,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","Clareon Vivity Pro IOL","Investigational UV-absorbing, blue-light filtering (BLF), foldable IOL that provides an extended range of vision from distance to near without increasing the incidence of visual disturbances.\n\nIOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.",[9,17],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Clareon Vivity IOL","Currently marketed UV-absorbing, BLF, foldable IOL that provides an extended range of vision from distance to functional near without increasing the incidence of visual disturbances.\n\nIOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.",[9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"TECNIS PureSee IOL","Currently marketed UV absorbing, violet-light filtering IOL for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia.\n\nIOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.",[17],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":27},"PROCEDURE","Cataract Surgery","Removal of the cloudy lens, followed by implantation of the IOL",[9,17],[42],{"name":43,"affiliation":44,"role":45},"Clinical Trial Lead, Surgical","Alcon Research, LLC","STUDY_DIRECTOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":27,"email":51},"Alcon Call Center","CONTACT","1-888-451-3937","alcon.medinfo@alcon.com",[53,67,76,82,91,101,111,120,132],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":27},"iVision Clinic","RECRUITING","Campsie","New South Wales","2194","Australia","AU",{"type":62,"coordinates":63},"Point",[64,65],151.10279,-33.9125,{"lat":65,"lon":64},{"facility":68,"status":55,"city":69,"state":57,"zip":70,"country":59,"countryCode":60,"cosmosGeoPoint":71,"geoPoint":75,"contacts":27},"Vision Eye Institute - Chatswood","Sydney","2067",{"type":62,"coordinates":72},[73,74],151.20732,-33.86785,{"lat":74,"lon":73},{"facility":77,"status":55,"city":69,"state":57,"zip":78,"country":59,"countryCode":60,"cosmosGeoPoint":79,"geoPoint":81,"contacts":27},"Personaleyes Parramatta","2150",{"type":62,"coordinates":80},[73,74],{"lat":74,"lon":73},{"facility":83,"status":55,"city":84,"state":57,"zip":85,"country":59,"countryCode":60,"cosmosGeoPoint":86,"geoPoint":90,"contacts":27},"Wollongong Eye Specialists","Wollongong","2500",{"type":62,"coordinates":87},[88,89],150.89345,-34.424,{"lat":89,"lon":88},{"facility":92,"status":55,"city":93,"state":94,"zip":95,"country":59,"countryCode":60,"cosmosGeoPoint":96,"geoPoint":100,"contacts":27},"Focus Vision","Woolloongabba","Queensland","4102",{"type":62,"coordinates":97},[98,99],153.03655,-27.48855,{"lat":99,"lon":98},{"facility":102,"status":55,"city":103,"state":104,"zip":105,"country":59,"countryCode":60,"cosmosGeoPoint":106,"geoPoint":110,"contacts":27},"Eye Surgery Associates - East Melbourne","East Melbourne","Victoria","3002",{"type":62,"coordinates":107},[108,109],144.9879,-37.81667,{"lat":109,"lon":108},{"facility":112,"status":55,"city":113,"state":104,"zip":114,"country":59,"countryCode":60,"cosmosGeoPoint":115,"geoPoint":119,"contacts":27},"Peninsula Eye Center","Mornington","3931",{"type":62,"coordinates":116},[117,118],145.03876,-38.21792,{"lat":118,"lon":117},{"facility":121,"status":55,"city":122,"state":123,"zip":124,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":131,"contacts":27},"Peregrine Eye Laser and Institute","Makati City","Manila","1209","Philippines","PH",{"type":62,"coordinates":128},[129,130],121.03269,14.55027,{"lat":130,"lon":129},{"facility":133,"status":55,"city":122,"state":27,"zip":134,"country":125,"countryCode":126,"cosmosGeoPoint":135,"geoPoint":137,"contacts":27},"Asian Eye Institute","1200",{"type":62,"coordinates":136},[129,130],{"lat":130,"lon":129},{"type":139,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100630170","contralateral-claims-study-of-clareon-vivity-pro-100630170",false,"NCT07484191","Contralateral Claims Study of Clareon Vivity Pro","Key Inclusion Criteria:\n\n* Cataracts in both eyes.\n* Preoperative corneal astigmatism of less than 1.00 diopter (D) in each eye.\n* Potential postoperative best corrected visual acuity (BCDVA) of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Desires monovision correction.\n* Predicted post-operative residual astigmatism of more than 1D in either eye.\n* Any ocular or systemic co-morbidity that, in the investigator's medical opinion, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject.\n* Other protocol-defined exclusion criteria may apply.","ALL","22 Years",{"count":149,"type":150},231,"ESTIMATED","INTERVENTIONAL",[153],"NA","The purpose of this study is to test new versions of Clareon Vivity Pro intraocular lenses (IOLs) by comparing them to currently marketed IOLs.",[156,157],"Aphakia","Presbyopia",[159,160,161],"Cataract","Eye Surgery","Intermediate Vision","2026-06-11",{"date":164,"type":165},"2026-06-15","ACTUAL",{"date":167,"type":165},"2026-04-28",{"date":169,"type":150},"2027-02",{"name":5,"class":6},9]